Cyrus has spoken softly, not even a word. Yet he speaks LOUD and CLEAR, speaking volumes without saying anything. He has gotten his point across.
Clues abound and you don't have to be a rocket scientist to decipher them.
Shorted, fought against even to the quarter dollar. For what? A few more pennies, or to destroy it entirely?
Yet, it has come back through clues.
Clearly, the commitment BOD made to us seems to be taking shape.
The Strategic thinking Cyrus was said to have, also seems to have truth behind it as I've reasoned here:
https://www.reddit.com/r/LeronLimab_Times/com...;context=3
What do we have currently?
CytoDyn did not need to tell the shareholders that a Type A meeting had taken place with FDA. They only told shareholders that they had the data and they knew what needed to be done to get the hold lifted. They assured shareholders they had a CRO for PharmacoVigilance on the job as well as senior director of clinical operations, Joe Meidling and VP of project management, Bernie Cunningham. They showed they have a regulatory consulting firm that assisted them in the preparation and review of the various regulatory communications, and lastly, that they had the data to work with an overall regulatory strategy advising group, who is one of the most reputable at being regulatory consulting firms led by former FDA regulators . They assured us it was an "All hands on deck effort".
Yesterday, it became obvious that the Warning for Leronlimab which was found on every one of CytoDyn's Webpages is no longer there. Clue? Does CytoDyn need to explicitly say the clinical hold has been lifted?
On the same day, another clue. An S3 which could have bee used to raise up to $200M was withdrawn. Why? CytoDyn no longer needs the money, or the money is coming yet, but from another source. Another source which first required that the clinical hold be lifted.
The withdrawal of the S3 was a "Clue" pointing to a Partnership that was in the making, yet, it was predicated on the hold first being lifted.
The removal of the warning from the webpage was yet another clue which points directly and says that the hold has been lifted.
CytoDyn indicated that the Type A meeting had taken place without even saying so by telling us they knew how to resolve the issue. Scott Kelly originally did not know how long that would take, but it is likely resolved.
Clues abound and you don't have to be a rocket scientist to decipher them.
Shorted, fought against even to the quarter dollar. For what? A few more pennies, or to destroy it entirely?
Yet, it has come back through clues.
Clearly, the commitment BOD made to us seems to be taking shape.
The Strategic thinking Cyrus was said to have, also seems to have truth behind it as I've reasoned here:
https://www.reddit.com/r/LeronLimab_Times/com...;context=3
What do we have currently?
CytoDyn did not need to tell the shareholders that a Type A meeting had taken place with FDA. They only told shareholders that they had the data and they knew what needed to be done to get the hold lifted. They assured shareholders they had a CRO for PharmacoVigilance on the job as well as senior director of clinical operations, Joe Meidling and VP of project management, Bernie Cunningham. They showed they have a regulatory consulting firm that assisted them in the preparation and review of the various regulatory communications, and lastly, that they had the data to work with an overall regulatory strategy advising group, who is one of the most reputable at being regulatory consulting firms led by former FDA regulators . They assured us it was an "All hands on deck effort".
Yesterday, it became obvious that the Warning for Leronlimab which was found on every one of CytoDyn's Webpages is no longer there. Clue? Does CytoDyn need to explicitly say the clinical hold has been lifted?
On the same day, another clue. An S3 which could have bee used to raise up to $200M was withdrawn. Why? CytoDyn no longer needs the money, or the money is coming yet, but from another source. Another source which first required that the clinical hold be lifted.
The withdrawal of the S3 was a "Clue" pointing to a Partnership that was in the making, yet, it was predicated on the hold first being lifted.
The removal of the warning from the webpage was yet another clue which points directly and says that the hold has been lifted.
CytoDyn indicated that the Type A meeting had taken place without even saying so by telling us they knew how to resolve the issue. Scott Kelly originally did not know how long that would take, but it is likely resolved.
5
